280 related articles for article (PubMed ID: 31685404)
1. Pharmacist recommendations for carbapenem de-escalation in urinary tract infection within an antimicrobial stewardship program.
Sadyrbaeva-Dolgova S; Aznarte-Padial P; Jimenez-Morales A; Expósito-Ruiz M; Calleja-Hernández MÁ; Hidalgo-Tenorio C
J Infect Public Health; 2020 Apr; 13(4):558-563. PubMed ID: 31685404
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of carbapenem de-escalation regardless of microbiological results: A propensity score analysis.
Sadyrbaeva-Dolgova S; Aznarte-Padial P; Pasquau-Liaño J; Expósito-Ruiz M; Calleja Hernández MÁ; Hidalgo-Tenorio C
Int J Infect Dis; 2019 Aug; 85():80-87. PubMed ID: 31075508
[TBL] [Abstract][Full Text] [Related]
4. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting.
Lew KY; Ng TM; Tan M; Tan SH; Lew EL; Ling LM; Ang B; Lye D; Teng CB
J Antimicrob Chemother; 2015 Apr; 70(4):1219-25. PubMed ID: 25473028
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Asakura T; Ikeda M; Nakamura A; Kodera S
Int J Infect Dis; 2014 Dec; 29():91-5. PubMed ID: 25461239
[TBL] [Abstract][Full Text] [Related]
6. Stewardship program on carbapenem prescriptions in a tertiary hospital for adults and children in France: a cohort study.
Poline J; Postaire M; Parize P; Pilmis B; Bille E; Zahar JR; Frange P; Cohen JF; Lortholary O; Toubiana J
Eur J Clin Microbiol Infect Dis; 2021 May; 40(5):1039-1048. PubMed ID: 33389261
[TBL] [Abstract][Full Text] [Related]
7. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
[TBL] [Abstract][Full Text] [Related]
8. Multicentre randomised controlled trial to investigate usefulness of the rapid diagnostic βLACTA test performed directly on bacterial cell pellets from respiratory, urinary or blood samples for the early de-escalation of carbapenems in septic intensive care unit patients: the BLUE-CarbA protocol.
Garnier M; Gallah S; Vimont S; Benzerara Y; Labbe V; Constant AL; Siami S; Guerot E; Compain F; Mainardi JL; Montil M; Quesnel C;
BMJ Open; 2019 Feb; 9(2):e024561. PubMed ID: 30782909
[TBL] [Abstract][Full Text] [Related]
9. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
Kim SA; Altshuler J; Paris D; Fedorenko M
Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
[TBL] [Abstract][Full Text] [Related]
10. Noncarbapenems for the Treatment of Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Bacteria.
White CW; Kyle JA; Deas CM; Campbell J
South Med J; 2019 Aug; 112(8):438-443. PubMed ID: 31375841
[TBL] [Abstract][Full Text] [Related]
11. Impact of antibiotic de-escalation on hospitalized patients with urinary tract infections: A retrospective cohort single center study.
Alshareef H; Alfahad W; Albaadani A; Alyazid H; Talib RB
J Infect Public Health; 2020 Jul; 13(7):985-990. PubMed ID: 32276874
[TBL] [Abstract][Full Text] [Related]
12. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.
Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
BMC Infect Dis; 2017 Apr; 17(1):279. PubMed ID: 28415969
[TBL] [Abstract][Full Text] [Related]
13. Acceptance and outcome of interventions in a meropenem de-escalation antimicrobial stewardship program in pediatrics.
Rungsitsathian K; Wacharachaisurapol N; Nakaranurack C; Usayaporn S; Sakares W; Kawichai S; Jantarabenjakul W; Puthanakit T; Anugulruengkitt S
Pediatr Int; 2021 Dec; 63(12):1458-1465. PubMed ID: 33740838
[TBL] [Abstract][Full Text] [Related]
14. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: are carbapenem alternatives achievable in daily practice?
Pilmis B; Delory T; Groh M; Weiss E; Emirian A; Lecuyer H; Lesprit P; Zahar JR
Int J Infect Dis; 2015 Oct; 39():62-7. PubMed ID: 26327124
[TBL] [Abstract][Full Text] [Related]
15. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study.
Fernando MM; Luke WA; Miththinda JK; Wickramasinghe RD; Sebastiampillai BS; Gunathilake MP; Silva FH; Premaratna R
BMC Infect Dis; 2017 Feb; 17(1):138. PubMed ID: 28187754
[TBL] [Abstract][Full Text] [Related]
16. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system.
Ahmad F; Pogue JM; Marchaim D; Chopra T; Bheemreddy S; Lee J; Mudegowdra NS; Chaudhry A; Kaye KS
J Infect Public Health; 2014 Feb; 7(1):50-3. PubMed ID: 24210246
[TBL] [Abstract][Full Text] [Related]
18. Compliance with carbapenem guidelines in a university hospital.
Van Hollebeke M; Chapuis C; Bernard S; Foroni L; Stahl JP; Bedouch P; Pavese P
Med Mal Infect; 2016 Mar; 46(2):72-8. PubMed ID: 26874673
[TBL] [Abstract][Full Text] [Related]
19. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
20. Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation.
Brizendine KD; Richter SS; Cober ED; van Duin D
Antimicrob Agents Chemother; 2015 Jan; 59(1):553-7. PubMed ID: 25385105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
